Intracellular delivery of charged therapeutic moieties to nerve cells by means of targeting proteins
CA 2436830 A1 · Owner: Asilomar Pharmaceuticals, Inc. · Inventors: Kahl, Stephen B.; Hill, Gordon Craig; Webb, Robert
Overview
Its claims, description and drawings are in the Canadian Patents Database.
Open the CIPO recordAbstract From the Canadian patent
A method for improving intercellular administration of a therapeutic agent is provided comprising: contacting cells with a compound comprising a charged derivative of a therapeutic agent, the charged derivative being conjugated to a protein having a biological activity of being transported across a cell membrane into a cell; and having the transport the compound into the cell where the cell metabolizes at least a portion of the compound to form a charged metabolite product that possesses the therapeutic activity of the therapeutic agent, the charged metabolite product being less prone to being transported across the cell membrane out of the cell relative to the compound and less …
Read the whole patent
Listed from its CIPO record in Patent Yard's archive of Canadian patents past their term. Its claims, description and drawings are in the CIPO record and on Google Patents, and the Claude kit works from them.
Why it's free to use
- Filed November 2, 2001. No grant is recorded for it in Canada; had it been granted, its 20-year term would have ended November 2, 2021.
- A certificate of supplementary protection adds at most two years for a drug, so even that would have ended by November 2, 2023.
- We check Canadian rights only. A patent in its family in another country could still be in force: check its family on Google Patents.
Timeline
Timeline From CIPO dates
Sources & verification
Official CIPO records
Everything on this page comes from the CIPO record linked above. Contains information licensed under the Open Government Licence – Canada.